Welcome to our dedicated page for Qualigen Therapeutics SEC filings (Ticker: QLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Qualigen Therapeutics, Inc. (historically NASDAQ: QLGN and now AIxCrypto Holdings, Inc. with symbol AIXC) provide detailed insight into the company’s transformation from a clinical-stage biotechnology issuer into a business that also emphasizes crypto, Web3, and decentralized AI activities. Through current reports on Form 8-K, registration statements on Form S-1, and proxy materials, investors can track how the company structures its financings, governs its operations, and discloses risks.
In its Form S-1 registration statement, the company outlines its current business mix: one early-clinical-stage program (QN-302), one preclinical Pan-RAS therapeutic program, and the C10 Cryptocurrency Asset Treasury with an 80% passive and 20% active allocation strategy to top cryptocurrencies. The S-1 also describes the terms of the Series B Convertible Preferred Stock, including conversion mechanics, voting rights, and the number of common shares that may be issued upon conversion, as well as the resale registration for those shares.
Multiple Form 8-K filings document the $41 million PIPE financing led by Faraday Future Intelligent Electric Inc., the Subscription Agreement and Registration Rights Agreement, and the Lead Investor Agreement that grants Faraday Future board nomination rights and participation rights in future financings. These filings also cover significant changes in senior management and the board of directors, the appointment and resignation of auditors, and Nasdaq correspondence regarding shareholder approval under Listing Rule 5635(b) and equity compliance under Listing Rule 5550(b)(1).
Additional filings, including the DEF 14A proxy statement, present the proposals submitted to stockholders, such as approval of the PIPE-related issuances and the 2025 Equity Incentive Plan. Name and ticker changes from Qualigen Therapeutics, Inc. (QLGN) to AIxCrypto Holdings, Inc. (AIXC) are recorded through amendments to the certificate of incorporation and related 8-K disclosures.
On Stock Titan’s filings page, users can review these documents as they are made available through EDGAR and use AI-powered summaries to understand complex items like preferred stock designations, treasury policies, and Nasdaq compliance matters. The page also surfaces key forms such as 10-Q and 10-K when filed, along with any future Form 4 insider transaction reports, to help readers analyze capital structure, governance developments, and the evolution of the company’s dual focus on therapeutics and AI × Web3 initiatives.
AIxCrypto Holdings, Inc. filed an update describing a new strategic focus and product progress rather than financial results. The company’s AIxC Hub platform has entered Season 2, adding new engagement mechanics and Tenki-based interactive modules to deepen AI agent-driven experiences.
Management, led by Co-CEO Jerry Wang, plans to concentrate resources on Real-World Asset (RWA) and Embodied AI (EAI) initiatives, including intelligent electric vehicles and AI robotics, while phasing out BesTrade AI Agent and Digital Asset AI Management modules to sharpen operational focus. The press release also highlights growing community traction, with the official X account reaching 53,417 followers, a 94% increase in engagement rates, and total impressions approaching 600,000, and reiterates extensive forward-looking statement cautions and risk factors.
AIxCrypto Holdings, Inc. detailed several new leadership and advisory arrangements. The company entered an Advisor Agreement with Yueting (YT) Jia, effective October 2, 2025, with a fixed annual fee of
The company also finalized a Co-CEO Employment Agreement for Jiawei Wang with a
Alpha Capital Anstalt, a Liechtenstein-based investor, filed Amendment No. 4 to report its beneficial ownership of ALXCRYPTO HOLDINGS, INC. common stock. It reports owning 36,003 shares, representing 0.51% of the company’s common stock based on 7,049,999 shares outstanding as of November 20, 2025.
Alpha Capital has sole voting and dispositive power over all 36,003 shares and no shared power. The filing confirms its holdings are below 5% of the class and states the shares were not acquired to change or influence control of ALXCRYPTO, indicating a passive investment position.
AIxCrypto Holdings, Inc. is registering up to 18,121,496 shares of common stock for resale by existing investors. This includes 337,432 shares already outstanding and 17,784,064 shares issuable upon conversion of 39,943 shares of Series B Convertible Preferred Stock at a conversion price of $2.246. The company will not receive proceeds from these resale transactions, though it previously raised $41 million in a private placement of common and Series B preferred stock that funded debt repayment, ongoing operations, and the launch of a cryptocurrency treasury strategy.
The filing describes a major strategic shift from a pure cancer therapeutics focus to a hybrid model combining oncology drug development with an actively managed crypto asset treasury. It highlights significant dilution potential, prior Nasdaq listing compliance challenges, substantial going concern doubts, a concentrated $4.8 million secured loan to Marizyme, and extensive risks tied to crypto market volatility, cybersecurity, and evolving global regulation.
AIxCrypto Holdings, Inc. (QLGN) reported that Nasdaq notified the company it had failed to comply with Listing Rule 5635(b), which requires shareholder approval before an issuance of securities that results in a change of control. The issue related to a
Nasdaq determined that this financing, together with significant board and management changes involving Faraday-affiliated individuals, constituted a change of control without prior shareholder approval. The company later obtained majority shareholder approval, and Nasdaq informed it that the deficiency was remediated and the matter closed, with no impact on the current listing of its common stock. Separately, on
AIxCrypto Holdings, Inc., formerly operating under the Nasdaq ticker QLGN, reported that it has launched a new corporate name and trading symbol “AIXC”. The company marked this rebranding with a presentation at Nasdaq headquarters, where it highlighted the new name and elements of an updated business plan focused on its AI and crypto-related strategy.
The company also issued a press release on November 20, 2025, announcing the rebranding and updated business plan, which is included as an exhibit to this report. A video link to the Nasdaq presentation was provided for investors and the public to review the company’s new positioning and strategic direction.
Qualigen Therapeutics, Inc. announced several board changes effective November 17, 2025. The Nominating and Governance Committee appointed Koti Meka, the Company’s Chief Financial Officer who also serves as CFO of Faraday Future Intelligent Electric Inc., as an Executive Director. The Committee also named Jie Sheng, Head of Operations & Finance Director of FF Global Partners LLC, as Chairman of the Board of Directors.
On the same date, Chad Chen, already a board member, was appointed to the Board’s Audit Committee. The Company states there are no compensation arrangements, plans, or agreements entered into with the newly appointed board members. Directors Graydon Bensler and Braeden Lichti resigned from the Board, and their resignations were noted as not resulting from any disagreements regarding the Company’s operations, policies, or practices.
Qualigen Therapeutics, Inc. reported that it has amended its charter in Delaware to change its corporate name to AIxCrypto Holdings, Inc. The company expects its common stock to stop trading under the ticker “QLGN” and begin trading on the Nasdaq Capital Market under the new symbol “AIXC” as promptly as possible. The name change does not alter the rights of existing stockholders.
At a 2025 special meeting, holders of approximately 60.17% of the voting stock were present, and a majority approved several key proposals. Stockholders approved a Subscription Agreement covering the private placement of 337,432 common shares and 39,943 shares of Series B Convertible Preferred Stock, the issuance of common shares upon conversion of that preferred stock in excess of a 19.99% share exchange cap, the company’s 2025 Equity Incentive Plan, and the ability to adjourn or postpone the meeting.
Qualigen Therapeutics, Inc. reported a net loss of
In September 2025, Qualigen closed a
Qualigen Therapeutics called a special stockholder meeting to seek approval for a recently closed private placement and related share issuances, conversion terms, and a new equity plan. Stockholders are asked to approve the Subscription Agreement and related transactions, including the prior sale of 337,432 shares of common stock and 39,943 shares of Series B Convertible Preferred Stock, and to allow conversion-related issuances above the Nasdaq 19.99% cap.
The Offering totaled $41,000,000 in cash. Series B Preferred carries a $1,000 stated value and is convertible at $2.246 per share after stockholder approval, subject to beneficial ownership limits. The company plans to use up to $6,800,000 of net cash proceeds to pay existing debt and fund operations, with the remainder and contributed currency for establishing cryptocurrency treasury operations.
Stockholders will also vote on a 2025 Equity Incentive Plan equal to 20% of common stock outstanding after the Offering, with a 10% annual evergreen increase through 2046, and on the ability to adjourn the meeting to solicit additional proxies if needed.